$0.13
-0.01 (-6.53%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.13
52W High$3.40
52W Low$0.14
Volume—
Avg Volume856.1K
Market Cap2.25M
P/E Ratio—
EPS$-4.45
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+22,111.0% upside
Current
$0.13
$0.13
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 804.0K | 1.14M | 3.56M |
| Net Income | -84,981,991 | -108,119,581 | 452.9K |
| Profit Margin | -10,567.2% | -10,038.8% | 12.7% |
| EBITDA | -85,792,372 | -115,214,522 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -29.3% | -29.3% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |